Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × mirdametinib × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

NF1 1 Multiple Myeloma 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Advanced Solid Tumor 1

Interventions

Cetuximab 39 Irinotecan 33 pembrolizumab 32 Oxaliplatin 32 Bevacizumab 32 Capecitabine 31 Fluorouracil 30 Leucovorin 29 Nivolumab 20 Gemcitabine 13 regorafenib 12 Cyclophosphamide 12 Folfox protocol 11 Cisplatin 10 Pemetrexed 9 Carboplatin 9 tislelizumab 8 Paclitaxel 8 IFL protocol 8 Panitumumab 7 130-nm albumin-bound paclitaxel 7 durvalumab 6 Ipilimumab 6 HMPL-013 6 Drug Therapy 6 irinotecan sucrosofate 5 Trifluridine 5 Specimen Handling 5 Interleukin-2 5 Everolimus 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02039336 2025-07-08

M13DAP

The Netherlands Cancer Institute

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡